Why AI Is Falling Short on Patient Engagement at Hospitals

New research shows that while health systems are pouring money into AI tools, most are still struggling to use the technology to meaningfully engage patients. Moving beyond generic outreach to “N-of-1 personalization” could be key to closing engagement gaps and improving patient outcomes at scale, said Amy Bucher, chief behavioral officer at Lirio. The post…

Read More

Deloitte’s 2026 Healthcare Outlook: Key Findings on Confidence, Digital Health, AI and Partnerships

Deloitte’s 2026 Healthcare Outlook shows that while more than two-thirds of U.S. healthcare leaders expect to outperform competitors, rising policy uncertainty is pushing greater focus on digital care, AI and partnerships. The post Deloitte’s 2026 Healthcare Outlook: Key Findings on Confidence, Digital Health, AI and Partnerships appeared first on MedCity News.

Read More

AHA Invests in AI that Tackles Cardiology’s Gender Bias Problem

The American Heart Association is backing an AI startup aimed at improving detection of hard-to-diagnose conditions like cardiac amyloidosis and heart failure with preserved ejection fraction (HFpEF). The company, named Ultromics, offers a platform that analyzes routine echocardiograms to help clinicians catch disease earlier, particularly for women who are more likely to be missed. The…

Read More

FDA Approval Puts New Cytokinetics Heart Drug in Competition With Fast-Growing BMS Med

Cytokinetics drug Myqorzo won FDA approval for treating obstructive hypertrophic cardiomyopathy, or oHCM. Compared to Bristol Myers Squibb’s projected blockbuster drug Camzyos, the Cytokinetics daily pill has less restrictive safety and monitoring requirements, giving it a competitive advantage, according to analysts. The post FDA Approval Puts New Cytokinetics Heart Drug in Competition With Fast-Growing BMS…

Read More